Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 21 versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 21 versus ENSKYCE.
BALZIVA-21 vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
BALZIVA-21 is administered 150 mg orally twice daily.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
12 hours (terminal); allows once-daily dosing in most patients
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive